DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-200-0200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.03 billion
Profitability
Miscellaneous
Employees2,800
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
DexCom (NASDAQ:DXCM) Frequently Asked Questions
What is DexCom's stock symbol?
DexCom trades on the NASDAQ under the ticker symbol "DXCM."
How were DexCom's earnings last quarter?
DexCom, Inc. (NASDAQ:DXCM) released its quarterly earnings data on Thursday, February, 21st. The medical device company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.16 by $0.38. The medical device company earned $338 million during the quarter, compared to the consensus estimate of $331.60 million. DexCom had a negative net margin of 12.32% and a positive return on equity of 4.98%. The business's revenue was up 52.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 EPS. View DexCom's Earnings History.
When is DexCom's next earnings date?
What guidance has DexCom issued on next quarter's earnings?
DexCom issued an update on its FY 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.175-1.225 billion, compared to the consensus revenue estimate of $1.18 billion.DexCom also updated its FY 2018 guidance to EPS.
What price target have analysts set for DXCM?
18 equities research analysts have issued 1 year price objectives for DexCom's shares. Their forecasts range from $125.00 to $175.00. On average, they anticipate DexCom's share price to reach $149.5333 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price. View Analyst Price Targets for DexCom.
What is the consensus analysts' recommendation for DexCom?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 6 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.
Has DexCom been receiving favorable news coverage?
Media coverage about DXCM stock has been trending somewhat positive this week, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DexCom earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned news headlines about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of DexCom's key competitors?
Some companies that are related to DexCom include Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), Hill-Rom (HRC), Insulet (PODD), Penumbra (PEN), Novocure (NVCR), ICU Medical (ICUI), Integra Lifesciences (IART), Globus Medical (GMED), Haemonetics (HAE), Tandem Diabetes Care (TNDM) and Merit Medical Systems (MMSI).
What other stocks do shareholders of DexCom own?
Who are DexCom's key executives?
DexCom's management team includes the folowing people:
- Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)
- Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)
- Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)
- Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)
- Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56)
Who are DexCom's major shareholders?
DexCom's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (5.55%), Brown Advisory Inc. (3.30%), Geode Capital Management LLC (1.17%), Norges Bank (1.01%), Mackenzie Financial Corp (0.86%) and Two Sigma Investments LP (0.82%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.
Which major investors are selling DexCom stock?
DXCM stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Brown Advisory Inc., Jennison Associates LLC, Frontier Capital Management Co. LLC, TD Asset Management Inc., Castleark Management LLC, Los Angeles Capital Management & Equity Research Inc. and Victory Capital Management Inc.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for DexCom.
Which major investors are buying DexCom stock?
DXCM stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Two Sigma Advisers LP, Two Sigma Investments LP, MERIAN GLOBAL INVESTORS UK Ltd, 1832 Asset Management L.P., Eagle Asset Management Inc., Bank of Nova Scotia and Westfield Capital Management Co. LP. View Insider Buying and Selling for DexCom.
How do I buy shares of DexCom?
Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DexCom's stock price today?
One share of DXCM stock can currently be purchased for approximately $145.80.
How big of a company is DexCom?
DexCom has a market capitalization of $13.12 billion and generates $1.03 billion in revenue each year. The medical device company earns $-127,100,000.00 in net income (profit) each year or $0.30 on an earnings per share basis. DexCom employs 2,800 workers across the globe.
What is DexCom's official website?
How can I contact DexCom?
DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]
MarketBeat Community Rating for DexCom (NASDAQ DXCM)
MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
